Ocugenix is developing therapies for angio-fibrotic diseases of the eye such as wet macular degeneration and diabetic retinopathy. These diseases are caused by an aberrant wound response in the back of the eye. Ocugenix’s compound triggers the process of wound resolution to cause the regression of the excessive fibrosis and vasculature recruited to heal the wound. The ability to cause regression of the pathological vessels and fibrosis in AMD and DR offers the patient the best hope of restoring lost sight.
Optimum Pumping Technology
Optimum Pumping creates state-of-the-art high-performance systems to the Natural Gas Pipeline industry that dramatically improves the reliability, efficiency, flow capacity and cost effectiveness of pumping station compressors and pipelines.
Optimus Technologies manufactures EPA-approved biodiesel conversion systems for medium and heavy-duty diesel trucks. Optimus’ engine technology enables fleets to reduce greenhouse gas emissions over 75% and reduce fuel costs by 10%.
Othot is a Saas-based platform that identifies the key strategic questions, called High Impact Questions™ (HIQs™) that matter most to your business. Rather than providing another data analysis tool, Othot starts with the end question in mind, and build a predictive analytics solution around that specific question.
Ottomatika, Inc. (acquired by Delphi Automative)
Ottomatika is a CMU spinout that has built a fully functional and globally publicized fully autonomous Cadillac SUV. The Company intends to become the leading vendor of advanced driving assistance and human-in-the-loop autonomous driving features to the automotive supply chain in a rapidly expanding market. Ottomatika’s proprietary technology is developed by an experienced world-class team at a time of intense industry interest in advanced driving features. Ottomatika’s total addressable market measures in multiple billions of dollars.